Ketamine for the treatment of chronic non-cancer pain

Bibliography

• Dahan A, Bauer M, Sarton E, What is considered long-term pain relief in chronic pain management? Pain 2010;149:410-11
   Web of Science ®Google Scholar
• Chizh BA. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 2007;21:259-71
   PubMed Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Salter MW. NMDA receptor in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742-55
   PubMed Web of Science ®Google Scholar
• Childers WE Jr, Baudy RB. N-methyl-D-Aspartate antagonists and neuropathic pain: the search for relief. J Med Chem 2007;50:2557-62
   PubMed Web of Science ®Google Scholar
• Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003;97:1730-9
   PubMed Web of Science ®Google Scholar
• Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology 2005;102:211-20
   PubMed Web of Science ®Google Scholar
• Bell RF. Topical review: ketamine for chronic non-cancer pain. Pain 2009;141:210-14
   PubMedGoogle Scholar
• Blonk MI, Koder BG, van den Bemt PMLA, Huygen FJPM. Use of oral ketamine in chronic pain management: a review. Eur J Pain 2010;14:466-72
   PubMed Web of Science ®Google Scholar
• Neil MJE. Survey on the use of ketamine infusions in Scottish hospitals. Pain News 2008; Summer issue:36-7
   Google Scholar
• Sigtermans MJ, van Hilten JJ, Bauer MCR, Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009;145:304-11
   PubMed Web of Science ®Google Scholar
• Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician 2010;13:245-9
   PubMed Web of Science ®Google Scholar
• Schwartzman RJ, Alexander GM, Grothusen JR, Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain 2009;147:107-15
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Ohtani M, Kariya S, Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003;24:37-43
   PubMed Web of Science ®Google Scholar
• Miller RD, Afton-Bird G, Fleisher LA. Miller's anesthesia. 6th edition. Elsevier Churchill Livingstone, Philadelphia; 2004
   Google Scholar
• Sigtermans M, Dahan A, Mooren M, S(+)-ketamine effect on experimental pain and cardiac output: a population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009;111:892-903
   PubMed Web of Science ®Google Scholar
• Ihmsen H, Geisslinger G, Schuttler J. Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine. Clin Pharmacol Ther 2001;70:431-8
   PubMed Web of Science ®Google Scholar
• Sigtermans M, Noppers I, Sarton E, An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in complex regional pain syndrome type 1 patients. Eur J Pain 2010;14:302-7
   PubMed Web of Science ®Google Scholar
• Yanagihara Y, Kariya S, Ohtani M, Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001;29:887-90
   PubMed Web of Science ®Google Scholar
• Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002;30:853-8
   PubMed Web of Science ®Google Scholar
• Leung LY, Baillie TA. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986;29:2396-9
   PubMed Web of Science ®Google Scholar
• Woolf TF, Adams JD. Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (E)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations. Xenobiotica 1987;17:839-47
   PubMed Web of Science ®Google Scholar
• Hagelberg NM, Peltoniemi MA, Saari TI, Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 2010;14:625-29
   PubMed Web of Science ®Google Scholar
• Sarton E, Teppema L, Olievier C, The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg 2001;93:1495-500
   PubMed Web of Science ®Google Scholar
• Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci 2009;29:600-9
   PubMed Web of Science ®Google Scholar
• Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-apartate (NMDA) receptors in pain: a review. Anesth Analg 2003;97:1108-16
   PubMed Web of Science ®Google Scholar
• Holtman JR, Crooks PA, Johnson-Hardy JK, Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 2008;90:676-85
   PubMed Web of Science ®Google Scholar
• Ayesh EE, Jensen TS, Svensson P. Effects of intra-articular ketamine on pain and somatosensory function in temporomandibular joint arthralgia patients. Pain 2008;137:286-94
   PubMed Web of Science ®Google Scholar
• Baad-Hansen L, Juhl GI, Jensen TS, Differential effect of S-ketamine and fentanyl on atypical odontalgia and capsaicin-evoked pain. Pain 2007;129:46-54
   PubMed Web of Science ®Google Scholar
• Backonja M, Arndt G, Gombar KA, Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 1994;56:51-7
   PubMed Web of Science ®Google Scholar
• Barton DL, Wos EJ, Mattar BL, A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 2010: published online 15 May 2010, doi:10.1007/s00520-010-0911-0
   Google Scholar
• Carr DB, Goudas LC, Denman WT, Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain 2004;108:17-27
   PubMed Web of Science ®Google Scholar
• Castrillon EE, Cairns BE, Emberg M, Effect of peripheral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: a randomized, double-blind, placebo-controlled trial. J Orofac Pain 2008;22:122-30
   PubMedGoogle Scholar
• Eichenberger U, Neff F, Svetici G, Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth Analg 2008;106:1265-73
   PubMed Web of Science ®Google Scholar
• Eide PK, Jorum E, Stubhaug A, Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. Pain 1994;58:347-54
   PubMed Web of Science ®Google Scholar
• Eide PK, Stubhaug A, Stenehjem A. Central dysesthesia after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery 1995;37:1080-7
   PubMed Web of Science ®Google Scholar
• Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 1995;64:283-91
   Web of Science ®Google Scholar
• Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind controlled trial of topical ketamine. Pain 2009;146:18-25
   PubMed Web of Science ®Google Scholar
• Furuhashi-Yonaha A, Iida H, Asano T, Short- and long-term efficacy of oral ketamine in eight chronic-pain patients. Can J Anaesth 2002;50:886-7
   Google Scholar
• Germain H. Use of locally injected sub-anesthetic doses of ketamine in chronic lumbar or cervical pain. Reg Anesth 1992;17(Suppl):58
   Google Scholar
• Gottrup H, Bach FW, Juhl G, Jensen TS. Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. Anesthesiology 2006;104:527-36
   PubMed Web of Science ®Google Scholar
• Graven-Nielsen T, Kendall SA, Henriksson KG, Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-91
   PubMed Web of Science ®Google Scholar
• Haines DR, Gaines SP. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain. Pain 1999;83:283-7
   PubMed Web of Science ®Google Scholar
• Huge V, Lauchart M, Magerl W, Effect of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur J Pain 2010;14:387-4
   PubMed Web of Science ®Google Scholar
• Jorum E, Warncke T, Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine – a double-blind, cross-over comparison with alfentanil and placebo. Pain 2003;101:229-35
   PubMed Web of Science ®Google Scholar
• Kvarnstrom A, Karlsten R, Quiding H, The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand 2003;47:868-77
   PubMed Web of Science ®Google Scholar
• Kvarnstrom A, Karlsten R, Quiding H, The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury. Acta Anaesthesiol Scand 2004;48:498-506
   PubMed Web of Science ®Google Scholar
• Lauretti GR, Rodrigues AM, Gomes JMA, dos Reis MP. Epidural ketamine versus epidural clonidine in the treatment of neuropathic chronic pain. Rev Brasil Anestesiol 2002;52:37-40
   Google Scholar
• Lemming D, Sorensen J, Graven-Nielsen T, The responses to pharmacological challenges and experimental pain in patients with chronic whiplash-associated pain. Clin J Pain 2005;21:412-21
   PubMed Web of Science ®Google Scholar
• Lemming D, Sorensen J, Graven-Nielsen T, Managing chronic whiplash associated pain with a combination of low-dose opioid (remifentanil) and NMDA-antagonist (ketamine). Eur J Pain 2007;11:719-32
   PubMed Web of Science ®Google Scholar
• Leung A, Wallace MS, Ridgeway B, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91:177-87
   PubMed Web of Science ®Google Scholar
• Lynch ME, Clarck AJ, Sawynok J. A pilot study examining topical amitryptiline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain 2003;19:323-8
   PubMed Web of Science ®Google Scholar
• Lynch ME, Clark AJ, Sawynok J, Sullivan MJL. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes. Anesthesiology 2005;103:140-6
   PubMed Web of Science ®Google Scholar
• Max MB, Byas-Smith MG, Gracely RH, Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharm 1995;18:360-8
   PubMed Web of Science ®Google Scholar
• Mitchell AC, Fallon MT. A single infusion of intravenous ketamine improves pain relief in patients with critical limb ischemia: results of a double blind randomised controlled trial. Pain 2002;97:275-81
   PubMed Web of Science ®Google Scholar
• Nicolodi M, Sicuteri F. Exploration of NMDA receptors in migraine: therapeutic and theoretic implications. Int J Clin Pharm Res 1995;15:181-9
   PubMedGoogle Scholar
• Nicolodi M, Sicuteri F. Modulation of excitatory amino acid pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drug abuse. Int J Clin Pharm Res 1997;17:97-100
   PubMedGoogle Scholar
• Nikolajsen L, Hansen CL, Nielsen J, The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain 1996;67:69-77
   PubMed Web of Science ®Google Scholar
• Persson J, Hasselstrom J, Wiklund B, The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans. Acta Anaesthesiol Scand 1998;42:750-8
   PubMed Web of Science ®Google Scholar
• Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspratate receptor inhibitor, in patients with chronic pain. J Pharmacol Exp Ther 1999;289:1060-6
   PubMed Web of Science ®Google Scholar
• Sorensen J, Bengtsson A, Ahlner J, Fibromyalgia – are there different mechanism in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997;24:1615-21
   PubMed Web of Science ®Google Scholar
• Vranken JH, Dijkgraaf MGW, Kruis MR, Iontophoretic administration of S(+)-ketamine in patients with intractable central pain: a placebo controlled trial. Pain 2005;118:224-31
   PubMed Web of Science ®Google Scholar
• Bell RF, Moore RA. Intravenous ketamine for CRPS: making too much of too little? Pain 2010;150:10-11
   PubMed Web of Science ®Google Scholar
• Kapural L, Stanton-Hicks M. What is considered long-term pain relief in chronic pain management? Pain 2010;149:409-10
   PubMed Web of Science ®Google Scholar
• Timm C, Linstedt U, Weiss T, Sympathomimetische Effekte auch bei niedriger Dosierungen von Esketamin. Anaesthesist 2008;57:338-46
   PubMed Web of Science ®Google Scholar
• Bubenikova-Valesova A, Horacek J, Vrajova M, Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008;32:1014-32
   PubMed Web of Science ®Google Scholar
• Tucker AP, Kim YI, Nadeson R, Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain. BMC Anesthesiology 2005;5:2
   PubMedGoogle Scholar
• Lipton SA. Pathological activated therapeutics for neuroprotection. Nat Rev Neurosci 2007;8:803-8
   PubMed Web of Science ®Google Scholar
• Curran HV, Monaghan L. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001;96:749-60
   PubMed Web of Science ®Google Scholar
• Winstock WK. Ketamine: from medicine to misuse. CNS Drugs 2006;20:199-218
   PubMed Web of Science ®Google Scholar
• Trujillo KA, Zamora JJ, Warmoth KP. Increased response to ketamine following treatment at long intervals: implications for intermittent use. Biol Psychiat 2008;63:178-83
   PubMed Web of Science ®Google Scholar
• Sikker W, Zou X, Hotchkiss CE, Ketamine-induced neuronal cell death in perinatal rhesus monkey. Toxicol Sci 2007;98:145-58
   PubMed Web of Science ®Google Scholar
• Jevtovic-Todorovic V, Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging 2005;26:947-56
   PubMed Web of Science ®Google Scholar
• Bergman SA. Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999;46:10-20
   PubMedGoogle Scholar
• Green SM, Cote CJ. Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. Ann Emerg Med 2009;54:181-90
   PubMed Web of Science ®Google Scholar